Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Drugs In Development, 2022, provides an overview of the Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline landscape.
Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 10, 11, 3, 17 and 4 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Overview
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Companies Involved in Therapeutics Development
Alucent Biomedical Inc
AnGes Inc
AptaBio Therapeutics Inc
ARCA biopharma Inc
Athera Biotechnologies AB
Athersys Inc
Betagenon AB
BiogenCell Ltd
Celularity Inc
Chengdu Shibeikang Biomedical Technology Co Ltd
Constant Therapeutics LLC
CuRAGE Therapeutics Inc
Exodos Life Sciences Limited Partnership
Foresee Pharmaceuticals Co Ltd
G&P Bioscience Co Ltd
Gurus BioPharm Inc
Helixmith Co Ltd
Hemostemix Inc
ID Pharma Co Ltd
IPCA Laboratories Ltd
JanOne Inc
LipimetiX Development Inc
LTT Bio-Pharma Co Ltd
MediaPharma SRL
Nangiotx Inc
Novo Nordisk AS
Pharmosa Biopharm Inc
Recardio Inc
Regio Biosciences
Resverlogix Corp
Reven Holdings Inc
Rnatives Ltd
Sanifit Therapeutics SA
Sorrento Therapeutics Inc
Symic Bio Inc
Vascugen Inc
Venturis Therapeutics Inc
VESSL Therapeutics Ltd
Vifor Pharma Ltd
Zelira Therapeutics Ltd
Zhittya Genesis Medicine Inc
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drug Profiles
AB-171 – Drug Profile
ACP-01 – Drug Profile
AEM-28 – Drug Profile
apabetalone – Drug Profile
AT-10 – Drug Profile
beperminogene perplasmid – Drug Profile
BGC-101 – Drug Profile
Cell Therapy for Cardiovascular Disease – Drug Profile
CR-3 – Drug Profile
CVBT-141 – Drug Profile
CVBT-141C – Drug Profile
donaperminogene seltoplasmid – Drug Profile
DVC-10101 – Drug Profile
ecraprost – Drug Profile
ELS-140 – Drug Profile
FGF-1 – Drug Profile
FP-045 – Drug Profile
GB-102 – Drug Profile
Gene Therapy for Cardiovascular, Dermatology and Neurology – Drug Profile
Gene Therapy for Peripheral Arterial Disease and End-Stage Kidney Disease – Drug Profile
GUR-602 – Drug Profile
INS-3001 – Drug Profile
invimestrocel – Drug Profile
L-220 – Drug Profile
LT-2003 – Drug Profile
miR-466 – Drug Profile
O-304 – Drug Profile
Ozempic – Drug Profile
PC-mAb – Drug Profile
PDA-002 – Drug Profile
Peptide for Peripheral Arterial Disease – Drug Profile
Protein 1 for Peripheral Arterial Disease and Wounds – Drug Profile
Protein for Peripheral Arterial Diseases and Wounds – Drug Profile
REC-03 – Drug Profile
REG-101 – Drug Profile
Rejuveinix – Drug Profile
resiniferatoxin – Drug Profile
RPCV-1004A – Drug Profile
SB-030 – Drug Profile
SBK-002 – Drug Profile
Small Molecule for Peripheral Arterial Disease – Drug Profile
Small Molecule to Inhibit NOX for Peripheral Vascular Disease – Drug Profile
Small Molecules to Agonize CB1 and CB2 for Diabetic Neuropathy and Peripheral Arterial Disease – Drug Profile
SNF-472 – Drug Profile
sodium nitrite SR – Drug Profile
Stem Cell Therapy for Diabetic Retinopathy, Peripheral Arterial Disease and Unspecified Cardiovascular Disorders, and Unspecified Indication – Drug Profile
TXA-302 – Drug Profile
V-10 – Drug Profile
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Dormant Projects
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Discontinued Products
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Product Development Milestones
Featured News & Press Releases
Jun 28, 2022: JanOne announces an improved formulation of JAN101
Jun 07, 2022: JanOne announces the issuance of U.S. patent covering a method of improving nerve function using JAN101
May 10, 2022: Hemostemix announces its intellectual property is back home
Jul 22, 2021: JanOne selects CPC Clinical Research as trial manager for phase 2b study of JAN101 for peripheral artery disease patients
Feb 10, 2021: Sanifit granted orphan drug designation by the FDA for SNF472 for the treatment of peripheral arterial disease in patients with end-stage kidney disease
Aug 26, 2020: JanOne advances its potential peripheral artery disease and Covid-19 vascular inflammation treatment towards trial readiness
Aug 21, 2020: JanOne to host telebriefing to discuss drug candidate JAN101 for treatment of peripheral artery disease (PAD) and potential applications for COVID-19 vascular complications
Aug 19, 2020: JanOne to present at The LD 500 Virtual Conference
Aug 11, 2020: JanOne completes stable formulation of JAN101 in preparation for its first GMP manufacturing batch to support upcoming clinical trials
Aug 06, 2020: JanOne engages CATO SMS, a world-leading CRO, to assist in the development of JAN101 to treat COVID-19 vascular complications
Aug 04, 2020: JanOne changes internal drug candidate name from TV1001SR to JAN101
Jul 21, 2020: JanOne receives FDA authorization for transfer of Investigational New Drug (IND) application for its Sodium Nitrite tablets
Jul 20, 2020: Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease
Jul 26, 2018: Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of FP-045, a Potent ALDH2 Activator
Jan 22, 2018: AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Universities/Institutes, 2022
Table 5: Products under Development by Companies, 2022
Table 6: Products under Development by Companies, 2022 (Contd..1)
Table 7: Products under Development by Companies, 2022 (Contd..2)
Table 8: Products under Development by Universities/Institutes, 2022
Table 9: Number of Products by Stage and Target, 2022
Table 10: Number of Products by Stage and Mechanism of Action, 2022
Table 11: Number of Products by Stage and Route of Administration, 2022
Table 12: Number of Products by Stage and Molecule Type, 2022
Table 13: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Alucent Biomedical Inc, 2022
Table 14: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by AnGes Inc, 2022
Table 15: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by AptaBio Therapeutics Inc, 2022
Table 16: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by ARCA biopharma Inc, 2022
Table 17: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Athera Biotechnologies AB, 2022
Table 18: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Athersys Inc, 2022
Table 19: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Betagenon AB, 2022
Table 20: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by BiogenCell Ltd, 2022
Table 21: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Celularity Inc, 2022
Table 22: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Chengdu Shibeikang Biomedical Technology Co Ltd, 2022
Table 23: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Constant Therapeutics LLC, 2022
Table 24: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by CuRAGE Therapeutics Inc, 2022
Table 25: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Exodos Life Sciences Limited Partnership, 2022
Table 26: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Foresee Pharmaceuticals Co Ltd, 2022
Table 27: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by G&P Bioscience Co Ltd, 2022
Table 28: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Gurus BioPharm Inc, 2022
Table 29: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Helixmith Co Ltd, 2022
Table 30: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Hemostemix Inc, 2022
Table 31: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by ID Pharma Co Ltd, 2022
Table 32: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by IPCA Laboratories Ltd, 2022
Table 33: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by JanOne Inc, 2022
Table 34: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by LipimetiX Development Inc, 2022
Table 35: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by LTT Bio-Pharma Co Ltd, 2022
Table 36: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by MediaPharma SRL, 2022
Table 37: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Nangiotx Inc, 2022
Table 38: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Novo Nordisk AS, 2022
Table 39: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Pharmosa Biopharm Inc, 2022
Table 40: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Recardio Inc, 2022
Table 41: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Regio Biosciences, 2022
Table 42: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Resverlogix Corp, 2022
Table 43: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Reven Holdings Inc, 2022
Table 44: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Rnatives Ltd, 2022
Table 45: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Sanifit Therapeutics SA, 2022
Table 46: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Sorrento Therapeutics Inc, 2022
Table 47: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Symic Bio Inc, 2022
Table 48: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Vascugen Inc, 2022
Table 49: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Venturis Therapeutics Inc, 2022
Table 50: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by VESSL Therapeutics Ltd, 2022
Table 51: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Vifor Pharma Ltd, 2022
Table 52: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Zelira Therapeutics Ltd, 2022
Table 53: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Zhittya Genesis Medicine Inc, 2022
Table 54: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Dormant Projects, 2022
Table 55: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Dormant Projects, 2022 (Contd..1)
Table 56: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Dormant Projects, 2022 (Contd..2)
Table 57: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Top 10 Targets, 2022
Figure 4: Number of Products by Stage and Top 10 Targets, 2022
Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Top 10 Routes of Administration, 2022
Figure 8: Number of Products by Stage and Top 10 Routes of Administration, 2022
Figure 9: Number of Products by Top 10 Molecule Types, 2022
Figure 10: Number of Products by Stage and Top 10 Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings